NurExone Biologic to Showcase ExoPTEN Therapy Innovations
NurExone Biologic Invited to Present at Key Conferences
NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) is excited to announce that its Chief Executive Officer, Dr. Lior Shaltiel, has been invited to present at prestigious upcoming conferences. This opportunity underscores the Company's commitment to advancing the field of exosomes for clinical applications and regenerative medicine.
ExoPTEN Therapy Presentation
Dr. Shaltiel will highlight NurExone's innovative ExoPTEN nanodrug, which shows promise as a potential treatment for acute spinal cord injuries and various central nervous system conditions, including glaucoma. His presentation will be centered around "A Comparative Analysis of AbbVie and NurExone's approaches to Effective Spinal Cord Injury Treatment". This conference serves as a significant event for bioprocessing and manufacturing, allowing engagement with industry leaders, researchers, and potential collaboration partners.
Participation Details
In addition to the Bioprocess International Conference, Dr. Shaltiel is also slated to be a panelist at the Pioneering Israel Medicine Conference. Here, he will share key insights into NurExone's leading work in the realm of exosomes for regenerative medicine. Notably, this event will also feature esteemed Nobel Prize Laureate Professor Aaron Ciechanover, adding further prestige to the gathering.
Significance of Exosome Technologies
The participation of Dr. Shaltiel at these influential conferences signifies NurExone's increasing presence and influence in the regenerative medicine space. The research and innovations presented are expected to resonate with numerous stakeholders keen on understanding the advancements being made in exosome technologies.
About NurExone Biologic Inc.
NurExone Biologic Inc. is a pharmaceutical company listed on the TSX Venture Exchange (TSXV) and OTCQB, focusing on the development of biologically-guided exosome-based therapies aimed at aiding patients with central nervous system injuries. The Company's flagship product, ExoPTEN, has shown remarkable efficacy, recovering motor functions in 75% of laboratory rats when administered intranasally. Additionally, the product has been granted Orphan Drug Designation by the FDA, highlighting its potential therapeutic benefits.
Innovative Drug Delivery Solutions
NurExone's platform technology is anticipated to present novel solutions for pharmaceutical companies interested in non-invasive drug delivery systems. With a focus on safety and efficacy, the innovation surrounding exosomes opens new avenues for treating various medical conditions.
Contact Information
For more information or inquiries, please reach out to:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Thesis Capital Inc.
Investor Relations - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr. Eva Reuter
Investor Relations - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations - US
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
Frequently Asked Questions
What is NurExone Biologic known for?
NurExone Biologic specializes in developing exosome-based therapies, particularly focusing on treating central nervous system injuries.
Who is Dr. Lior Shaltiel?
Dr. Lior Shaltiel is the Chief Executive Officer of NurExone Biologic Inc., leading the company's innovative research initiatives.
What are ExoPTEN's applications?
ExoPTEN is being explored as a treatment for acute spinal cord injuries and other central nervous system conditions.
What prestigious events will NurExone participate in?
NurExone will participate in the Bioprocess International Conference and the Pioneering Israel Medicine Conference.
How effective is ExoPTEN based on studies?
ExoPTEN has shown a significant recovery of motor function in 75% of laboratory rats when administered intranasally.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.